انشىء مدونتك الخاصة | تسجيل الدخول
المدونة التالية

الأميركيات الأفارقة أكثر عرضة لتكرر الإصابة:التوت البري الأسود لمحاربة سرطان الأمعاءواشنطن - ي ب ا
04 تشرين ثاني, 2010

 

Black raspberries could help prevent bowel cancer, according to scientists

By Daily Mail Reporter
Last updated at 12:38 AM on 3rd November 2010

Black raspberries contain powerful antioxidants which have been proven to suppress tumour development

Black raspberries contain powerful antioxidants which have been proven to suppress tumour development

Black raspberries may help prevent bowel cancer, new research suggests.

Scientists found that a freeze-dried version of the fruit could reduce the number of tumours in a strain of mice prone to the disease by 60 per cent.

The incidence of bowel tumours was cut by 45 per cent.

Previous research had indicated that black raspberries have antioxidant and anti-cancer properties.

In the study, the fruit inhibited tumour development by suppressing a protein called beta-catenin.

Tumour incidence and numbers were both reduced by 50 per cent in another strain of mouse vulnerable to colitis, an inflammation of the large intestine that can contribute to bowel cancer.

"We saw the black raspberry as a natural product, very powerful, and easy to access," said study leader Dr Wancai Yang, from the University of Illinois in Chicago.

The findings were published today in the journal Cancer Prevention and Research.

Both mouse strains were either fed a Western-style, high fat diet, or the same diet supplemented with 10 per cent freeze-dried black raspberry powder for 12 weeks.

Scientists saw a broad range of protective effects in the bowels of the mice given the supplement.

Black raspberries are native to the US and are a popular fruit among home gardeners, although they are less common in the UK.

التوت البري الأسود لمحاربة سرطان الأمعاء

واشنطن - ي ب ا

    أظهرت دراسة جديدة أن التوت البري الأسود قد يساعد في الوقاية من سرطان الأمعاء.

وتبيّن في الدراسة الجديدة التي أجراها فريق علماء في جامعة أوهايو أن هذه الفاكهة توقف نمو الورم عبر قمع بروتين اسمه "بيتا كاتينين"، وذلك من خلال مركّب اسمه "أنتوسيانين" الذي يعطيها لونها الأسود إضافة إلى فيتامينات مكافحة للسرطان ومعادن وحوامض.

وقال أحد المشاركين في الدراسة، البروفسور في كلية الطب بجامعة أوهايو غاري ستونر لموقع "هلث نيوز" الأميركي انه بسبب النسبة العالية من هذا المركّب يتمتع التوت البري بنشاط كبير مضاد للأكسدة وهو ما يجعله فعالاً جداً في محاربة الخلايا السرطانية.

وتوصّل العلماء إلى أن التوت البري المجفف والمجلّد منع تشكّل الأورام الخبيثة في أمعاء فئران معدّة للإصابة بسرطان الأمعاء، بنسبة 45%. وإذا تم التوصّل إلى النتائج ذاتها عند البشر فقد تستخدم هذه الفاكهة في تفادي سرطان الأمعاء

 

=================

 

 

الأميركيات الأفارقة أكثر عرضة لتكرر الإصابة

نوع العِرق البشري قد يؤثر على تكرر الإصابة بسرطان الرحم

واشنطن - ي ب ا :

    أظهرت دراسة أميركية جديدة أن نوع العِرق البشري قد يؤثر على تكرر الإصابة بسرطان الرحم رغم الاستئصال الكامل للرحم أو معالجة المرض عبر الأشعة.

وأفاد موقع "ساينس ديلي" الاميركي عن الباحثين في مستشفى "هنري فورد" أن الأميركيات الأفارقة هن على الأرجح أكثر عرضة لتكرر الإصابة بسرطان الرحم حتى بعد استئصاله ومعالجته بالأشعة.

ونقلت عن المسؤول عن الدراسة الطبيب محمد الشيخ قوله إنه " أجري للمريضات الأميركيات الأفارقة في دراستنا جراحات وعلاج بالأشعة مماثل للمرضى القوقازيين"، وكانت النتيجة أن الأوائل تكررت عندهن الإصابة بالمرض.

وأضاف "في هذه المرحلة، ستكون الخطوة اللاحقة النظر بإمعان في البيولوجيا الجزئية لهذه الخلايا السرطانية من اجل المساعدة على تحديد سبب أن العرق هو مؤشر سلبي لمحصلة سرطان الرحم".

ووجدت الدراسة أيضاً أن مرحلة المرض وعمر المريضة يشكلان عاملي خطر لتكرر الإصابة بسرطان الرحم

African Americans more likely to have uterine cancer recurrence

2. November 2010 05:36

 

African Americans are more likely to have a recurrence of uterine

 

cancer despite undergoing a total hysterectomy or a hysterectomy followed by radiation therapy, according to researchers at Henry Ford Hospital in Detroit.

"The African American patients in our study had similar surgeries and radiation therapy as the Caucasian patients in the study. So access to care certainly wasn't a factor in race being identified as a negative predictor for outcome," says lead author Mohamed Elshaikh, M.D., senior staff physician in the Department of Radiation Oncology at Henry Ford Hospital.

"At this point, our next step is to take a closer look at the underlying molecular biology of these cancer cells to help identify a cause for race being a negative predictor for uterine cancer outcome."

This retrospective study - one of the largest of its kind with 750 uterine cancer patients - will be presented Nov. 2 at the 52nd annual American Society for Radiation Oncology (ASTRO) meeting in San Diego. Results also are now online in the November issue of the International Journal of Radiation Oncology

 

 

What's notable about our study is that we were able to confirm on a larger scale the known prognostic factors in uterine cancer, and also identify African American race as a negative predictor for outcome despite adequate surgery and radiation treatment," says Dr. Elshaikh.

Endometrial cancers mainly arise from the tissue lining the uterus. They are the most common gynecologic cancers in the United States, with more than 43,000 women diagnosed and an estimated 7,950 dying from the disease in 2010, according to the National Cancer Institute. The most common type, endometrioid adenocarcinoma, typically occurs within a few decades of menopause.

While a total hysterectomy (surgical removal of the uterus) is the most common therapeutic approach, treating physicians often differ on the next step for treatment after surgery. Some recommend radiation treatment, while others recommend no further treatment.

For the Henry Ford study, Dr. Elshaikh and his colleagues identified 750 patients with stage I or II uterine cancer who underwent a total hysterectomy between 1987 and 2008. The median age was 64, and 30 percent of the study group were African American.

The study was limited to those patients who underwent surgery and received no further treatment, and those who underwent surgery and had radiation therapy.

Recurrence-free survival for the study group at 5 years and 10 years was 94 percent and 93 percent, respectively.

The median time for uterine cancer recurrence among the group was 1.2 years.

The site of recurrence was primarily vaginal (74 percent) for those who did not receive radiation therapy.

The study also found that higher tumor grade and cancer stage, along with age (older than 65), were risk factors for uterine cancer returning after treatment. African American patients in the study also were more likely to have their cancer return than Caucasian patients.

Source: Henry Ford Health System

 

تعليقات

اضافة تعليق
authimage
رمز التأكيد
A service provided by Al Bawaba